Study guide
7.1 Newborn Examination & Early Postnatal Care
ABFM Family Medicine Certification Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making
1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care
2 Chapter 2: Healthcare Systems, Practice Management & Quality
2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination
3 Chapter 3: Ethics, Law, Biostatistics & Health Equity
3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism
4 Chapter 4: Lifestyle Counseling & Behavior Change
4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling
5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention
5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling
6 Chapter 6: Routine Adult Immunizations
6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise
7 Chapter 7: Pediatric Health Maintenance & Surveillance
7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride
8 Chapter 8: Behavioral Health & Safety Screening
8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling
9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic
9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening
10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic
10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling
11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate
11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making
12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception
12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C
13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care
13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam
14 Chapter 14: Emergent Cardiovascular Conditions
14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies
15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises
15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management
16 Chapter 16: Vascular & Thromboembolic Emergencies
16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion
17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness
17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion
18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies
18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies
19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies
19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice
20 Chapter 20: Acute Pulmonary & Airway Emergencies
20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction
21 Chapter 21: Acute Traumatic Injuries & Wound Care
21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites
22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies
22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises
23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies
23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection
24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies
24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis
25 Chapter 25: Hematologic, Urologic & Dental Emergencies
25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma
26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies
26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia
27 Chapter 27: Acute Head, Neck & Neurologic Symptoms
27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring
28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms
28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis
29 Chapter 29: Acute Upper Respiratory Tract Infections
29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion
30 Chapter 30: Acute Lower Respiratory Infections & Cough
30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia
31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions
31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation
32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms
32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation
33 Chapter 33: Acute Upper Gastrointestinal Conditions
33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness
34 Chapter 34: Acute Lower Gastrointestinal Conditions
34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani
35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders
35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes
36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders
36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis
37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions
37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation
38 Chapter 38: Acute Infectious Dermatoses
38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum
39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses
39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma
40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries
40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains
41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries
41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes
42 Chapter 42: Acute Ambulatory Fractures & Dislocations
42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation
43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls
43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients
44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain
44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies
45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions
45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction
46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions
46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation
47 Chapter 47: Acute Women's Health & Early Pregnancy Care
47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder
48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination
48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis
49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections
49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses
50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia
50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT
51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases
51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy
52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD
52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria
53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus
53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance
54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases
54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition
55 Chapter 55: Chronic Endocrine Disorders
55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders
56 Chapter 56: Chronic Kidney Disease & Venous Disorders
56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD
57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases
57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy
58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care
58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders
59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders
59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome
60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders
60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care
61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders
61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness
62 Chapter 62: Chronic Psychiatric Disorders
62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder
63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions
63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating
64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation
64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy
65 Chapter 65: Chronic Dermatologic Conditions
65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus
66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care
66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control
67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit
67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit
7.1 Newborn Examination & Early Postnatal Care
Key Takeaways Explain This Topic AI
Caput succedaneum represents benign subcutaneous serosanguinous fluid crossing cranial suture lines and resolving in days; cephalohematoma is a subperiosteal hemorrhage bound by suture lines taking weeks to resolve and carrying hyperbilirubinemia risk; subgaleal hemorrhage traverses suture lines beneath the epicranial aponeurosis and represents a life-threatening hypovolemic emergency.
Developmental Dysplasia of the Hip (DDH) is evaluated with Barlow (dislocating: adduction + posterior pressure) and Ortolani (reducing: abduction + anterior lift) maneuvers; breech presentation in the third trimester warrants screening bilateral hip ultrasound at 4 to 6 weeks of age, deferring plain radiographs until 4 to 6 months when femoral heads ossify.
Pathologic neonatal hyperbilirubinemia manifests as jaundice within the first 24 hours of life, total bilirubin rise >0.2 mg/dL/hr, total bilirubin >95th percentile on the Bhutani nomogram, or direct/conjugated bilirubin >1.0 mg/dL (or >20% of total); acute bilirubin encephalopathy presents with lethargy, retrocollis, and high-pitched cry, progressing to permanent choreoathetoid cerebral palsy and sensorineural hearing loss (kernicterus).
Mandatory routine newborn prophylaxis includes intramuscular vitamin K1 (phytomenadione 0.5-1.0 mg) within 6 hours to prevent early, classic, and late (intracranial) vitamin K deficiency bleeding; erythromycin 0.5% ophthalmic ointment within 24 hours to prevent gonococcal ophthalmia (ineffective against Chlamydia); and hepatitis B vaccination within 24 hours (with HBIG within 12 hours if maternal HBsAg is positive or unknown).
The state dried blood spot panel collected at 24 to 48 hours screens for core inborn errors of metabolism including PKU, congenital hypothyroidism, galactosemia, hemoglobinopathies (prompting penicillin prophylaxis by 2 months), cystic fibrosis, and severe combined immunodeficiency (SCID via TREC quantification).
Last updated: September 2026
The Comprehensive Newborn Physical Examination
The initial neonatal examination represents a critical transition point in family medicine, serving both as an acute screening evaluation for life-threatening congenital anomalies and birth trauma, and as the baseline for longitudinal health supervision. A structured, head-to-toe examination must be conducted within the first 24 hours of life, performed in a warm, well-illuminated environment under radiant heat to prevent cold stress.
Gestational Age Assessment: The New Ballard Score
Accurate assessment of gestational age is essential for classifying infants as preterm (<37 weeks), term (37 0/7 to 41 6/7 weeks), or post-term (≥42 weeks), and identifying infants who are small for gestational age (SGA, birth weight <10th percentile), appropriate for gestational age (AGA, 10th to 90th percentile), or large for gestational age (LGA, >90th percentile). The New Ballard Score assesses six neuromuscular and six physical maturity characteristics, yielding an aggregate score (-10 to 50) that correlates directly with gestational maturity (ranging from 20 to 44 weeks):
Neuromuscular Maturity Criteria
Posture : Evaluates resting tone in the supine position. Immature preterm infants demonstrate complete flaccidity and extension (score 0), with progressive development of flexion beginning in the lower extremities and advancing cephalad toward the upper extremities (score 4 demonstrates brisk full flexion of all four limbs).
Square Window : Measures the angle of flexibility at the wrist by gently flexing the infant's hand toward the volar forearm. The angle decreases from >90° in extreme preemies to 0° (the hypothenar eminence contacts the forearm) in full-term infants.
Arm Recoil : Tests passive flexor tone of the biceps. The examiner flexes the forearms for 5 seconds, fully extends them, and releases. Recoil is absent or minimal in preterm infants (<90° recoil), whereas term infants exhibit rapid, vigorous flexion (<90° angle formed at the elbow upon release).
Popliteal Angle : Assesses resistance of the hamstring muscles to knee extension with the pelvis flat on the table and the thigh held vertically. Preterm neonates have minimal hamstring resistance (popliteal angle 180°), whereas term neonates resist extension, yielding an angle of <90°.
Scarf Sign : Evaluates passive tone of the shoulder girdle. The examiner grasps the infant's hand and attempts to pull the arm across the chest toward the opposite shoulder. In premature infants, the elbow easily traverses the midline to the opposite acromion (score -1 or 0). In term infants, the elbow meets stiff resistance and cannot cross the mid-clavicular line or midline of the sternum.
Heel-to-Ear : Assesses tone of the pelvic girdle. With the infant supine and pelvis flat, the foot is drawn toward the ipsilateral ear. Preterm infants exhibit minimal resistance (heel touches the ear, score 0). Full-term infants demonstrate significant popliteal resistance, with the foot stopping well before reaching the chest or face (score 4).
Physical Maturity Criteria
Skin : Gelatinous, red, translucent, and friable in extreme prematurity; transitions to smooth, pink skin with visible veins; in post-term infants, skin becomes pale, thick, cracked, leathery, and wrinkled with absence of visible vessels.
Lanugo : Fine downy hair is absent in extreme prematurity (20 weeks), becomes abundant and dense across the back and shoulders at 28 to 30 weeks, and progressively thins and sheds, leaving bald areas or absent lanugo at term.
Plantar Surface : Creases appear initially on the anterior third of the sole at 32 to 34 weeks, progressing to cover the anterior two-thirds by 37 weeks, and forming deep cracking over the entire sole in term and post-term infants.
Breast Bud : Areola is imperceptible and flat without a palpable bud in early gestation; by term, a raised, stippled areola with a firm, glandular breast bud measuring 5 to 10 mm in diameter is palpable.
Eye and Ear : Eyelids are fused in extreme preemies (opening by 26 to 28 weeks). The pinna is flat, shapeless, and stays folded when bent in preterm infants; by term, the pinna is well-curved, firm with cartilaginous stiffening, and exhibits instant recoil when folded.
Genitalia (Male) : In preterm males, the scrotum is flat, smooth, and empty with undescended testes. By term, the testes are fully descended into a pendulous scrotum covered by deep, rugated folds.
Genitalia (Female) : In premature females, the clitoris is prominent and labia minora are completely exposed. By term, the labia majora enlarge and completely cover the clitoris and labia minora.
Normal Neonatal Vital Signs
Baseline vital signs must be recorded when the infant is quiet and resting:
Heart Rate : Normal resting range is 110 to 160 beats per minute (bpm) . Rates may transiently decelerate to 85 to 100 bpm during deep sleep, or accelerate up to 180 bpm during vigorous crying. Persistent tachycardia (>160 bpm) or bradycardia (<100 bpm) warrants immediate electrocardiographic and hemodynamic evaluation.
Respiratory Rate : Normal range is 30 to 60 breaths per minute . Neonates exhibit periodic breathing , characterized by brief pauses in respiration lasting 5 to 10 seconds followed by rapid compensatory breathing for 10 to 15 seconds, without associated cyanosis, pallor, or bradycardia; this is a benign, normal physiologic finding. In contrast, true apnea is defined as cessation of breathing for >20 seconds , or any pause accompanied by cyanosis, pallor, hypotonia, or bradycardia (<100 bpm), representing a pathologic sign of sepsis, intracranial hemorrhage, metabolic derangement, or hypothermia.
Temperature : Normal axillary temperature is 36.5°C to 37.5°C (97.7°F to 99.5°F) . Neonates are obligate homeotherms with high surface-area-to-mass ratios and limited subcutaneous insulating fat. Neonatal hypothermia triggers cold stress, inducing non-shivering thermogenesis via brown fat lipolysis, which dramatically increases oxygen consumption, causes pulmonary vasoconstriction, and precipitates hypoglycemia and metabolic lactic acidosis.
Blood Pressure : Mean systolic blood pressure ranges from 60 to 80 mmHg and diastolic from 40 to 50 mmHg on day 1 of life in term infants. Four-extremity blood pressures are indicated whenever femoral pulses are weak or delayed to evaluate for coarctation of the aorta (upper-extremity systolic pressure >10-15 mmHg higher than lower extremities).
Cranial Birth Injuries & Fontanelle Assessment
Parturition exerts immense compressive and shear forces across the fetal cranium, particularly during prolonged second-stage labor, precipitous delivery, cephalopelvic disproportion, or operative vaginal delivery (vacuum extraction or forceps). Differentiating benign cranial fluid collections from life-threatening intracranial or subaponeurotic hemorrhages is a high-yield ABFM clinical competency.
Master Comparison: Cranial Birth Injuries
Clinical Parameter Caput Succedaneum Cephalohematoma Subgaleal Hemorrhage
Anatomical Plane Subcutaneous tissue overlying the galea aponeurotica / epicranial aponeurosis Subperiosteal space between cranial periosteum and skull bone Subgaleal space between galea aponeurotica and cranial periosteum
Crosses Suture Lines? YES ; fluid crosses midline and cranial sutures freely NO ; strictly bounded and restricted by periosteal suture attachments YES ; traverses suture lines and can expand into orbits and nape of neck
Onset of Swelling Present immediately at birth Appears hours to 1–2 days after birth as subperiosteal bleed slowly accumulates Progressive, rapid expansion over hours to days post-delivery
Palpatory Quality Soft, pitting, boggy, poorly circumscribed edema with overlying ecchymosis Firm, tense, fluctuant, sharply demarcated margins; may feel like a depressed skull fracture Diffuse, massive fluctuant fluid wave, boggy, shifting dependent swelling
Spontaneous Resolution Resolves spontaneously within 2 to 4 days Resolves slowly over 2 to 8 weeks ; may undergo peripheral calcification Does NOT resolve spontaneously; high mortality without active ICU resuscitation
Systemic Risk & Complications Benign; minimal clinical significance Hyperbilirubinemia (RBC hemolysis), underlying linear skull fracture (~5%) Hemorrhagic shock , massive hypovolemia (can sequester >50% of blood volume), death
Management Strategy Reassurance; no therapy required Observation; contraindicated to aspirate (introduces fatal infection); monitor bilirubin Emergent NICU admission, serial head circumference, PRBC transfusion, shock resuscitation
Cranial Fontanelles and Sutures
Anterior Fontanelle : Diamond-shaped, located at the junction of the sagittal, coronal, and frontal sutures. Measures 1 to 4 cm in diameter. Normal closure occurs between 9 and 18 months of age . A sunken or depressed anterior fontanelle is a sensitive sign of significant dehydration. A tense, bulging anterior fontanelle in a non-crying, upright infant signifies elevated intracranial pressure (meningitis, intracranial hemorrhage, hydrocephalus, or hypovitaminosis A). Abnormally large or delayed fontanelle closure (>24 months) suggests congenital hypothyroidism, rickets, trisomy 21 (Down syndrome), or achondroplasia.
Posterior Fontanelle : Triangular, situated at the junction of the sagittal and lambdoid sutures. Measures 0.5 to 1 cm at birth. Closes early, typically by 1 to 2 months of age . A persistently wide or enlarged posterior fontanelle (>1 cm) at birth is a valuable early clinical indicator of congenital hypothyroidism.
Craniosynostosis : Premature pathologic fusion of one or more cranial sutures, restricting skull expansion perpendicular to the fused suture and forcing compensatory overgrowth parallel to it. Sagittal synostosis causes scaphocephaly (long, narrow head); coronal synostosis causes brachycephaly (flattened, broad forehead); metopic synostosis causes trigonocephaly (triangular forehead). Differentiated from benign positional plagiocephaly (parallelogram-shaped head from supine sleeping with ipsilateral ear displaced anteriorly) by palpation of a rigid bony ridge along the closed suture and lack of movement with cranial repositioning. Suspected craniosynostosis requires pediatric neurosurgical evaluation and cranial CT/reconstruction.
- Ophthalmologic, Oral, and Clavicular Examination
- The Red Reflex (Bruckner Test)
The red reflex must be examined in every newborn prior to hospital discharge using a direct ophthalmoscope set at 0 diopters viewed from a distance of 12 to 18 inches in a darkened room. Normal examination reveals symmetrical, homogeneous, bright reddish-orange reflections from both retinas.
Leukocoria (White Pupillary Reflex) : An abnormal white reflex in one or both eyes is a medical emergency. The most critical differential diagnosis is retinoblastoma , the most common primary intraocular malignancy of childhood. Other causes include congenital cataracts, persistent fetal vasculature (persistent hyperplastic primary vitreous), retinopathy of prematurity (ROP), and chorioretinitis (e.g., congenital toxoplasmosis, CMV). Any infant with leukocoria, asymmetric red reflexes, or dark spots within the reflex requires immediate same-day or urgent pediatric ophthalmology referral .
Oral Cavity and Palate Examination
The oral cavity requires direct visual inspection under light and digital palpation of both the hard and soft palates with a gloved finger to evaluate intact anatomy and sucking reflex.
Cleft Lip and Palate : Cleft lip results from failure of the maxillary prominence to fuse with the medial nasal prominence at 6 to 7 weeks of gestation; cleft palate results from failure of the lateral palatine processes to fuse at 7 to 12 weeks. Submucous cleft palates can be occult, presenting with feeding difficulties and nasal regurgitation; examination reveals a bifid uvula , a palpable bony notch at the posterior edge of the hard palate, and a translucent central midline stripe (zona pellucida) in the soft palate.
Natal Teeth : Primary teeth present at birth (usually mandibular central incisors). If loose, mobile, and lacking root structure, they must be extracted promptly to prevent aspiration; if firmly fixed, they may be preserved.
Epstein Pearls : Benign, small (1–2 mm), white-yellow keratin-containing cysts found along the median palatal raphe in up to 80% of newborns. They represent trapped epithelial inclusions, cause no symptoms, and resolve spontaneously within several weeks without treatment.
Clavicle Fracture
The clavicle is the most commonly fractured bone during birth, occurring in up to 2% of deliveries. Risk factors include fetal macrosomia (birth weight >4,000 g), shoulder dystocia, operative delivery (vacuum or forceps), and maternal diabetes.
Clinical Signs : Focal crepitus, edema, bony irregularity, point tenderness, and irritability when moving the affected arm. On neurological testing, the infant demonstrates an asymmetric or absent Moro reflex on the affected side , while the palmar grasp reflex remains completely intact. (If the palmar grasp is absent or the arm hangs flaccidly in internal rotation and adduction with forearm pronation, brachial plexus injury [Erb's palsy, C5-C6 roots] or Klumpke's palsy [C8-T1 roots] is present).
Management : Reassurance and parental education. Fracture healing is rapid and benign; immobilization is achieved simply by pinning the infant's shirt sleeve to the front of the clothing with the elbow bent in gentle flexion for comfort. A prominent, hard callus forms within 2 to 4 weeks and remodels completely over several months.
Developmental Dysplasia of the Hip (DDH)
Developmental Dysplasia of the Hip (DDH) encompasses a dynamic spectrum of hip abnormalities ranging from mild acetabular dysplasia (shallow acetabular roof) to hip subluxation and complete, frank dislocation of the femoral head from the acetabulum.
Risk Factors for DDH
Breech Presentation : The single strongest mechanical risk factor, especially persistent frank breech in the third trimester (≥34 weeks). Breech positioning forces the hips into extreme flexion with knees extended, stretching the posterior capsule.
Female Sex : Females account for ~80% of DDH cases, secondary to heightened physiological sensitivity to maternal circulating relaxin and estrogens, promoting transient ligamentous laxity.
Family History : Positive family history in a first-degree relative increases risk threefold.
Firstborn Status and Oligohydramnios : Inelastic primiparous uterus and low amniotic fluid increase mechanical molding and restricted fetal movement.
Postnatal Swaddling Practices : Traditional tight swaddling with lower extremities strapped in forced extension and adduction significantly increases the incidence of secondary hip dysplasia; hips should instead be swaddled loosely with thighs maintained in flexion and abduction ("hip-healthy swaddling").
Clinical Physical Examination Maneuvers
Physical examination of the neonatal hip requires a relaxed, calm infant on a firm, flat examination surface. Each hip must be examined individually while stabilizing the contralateral pelvis:
Barlow Maneuver (The Dislocation Test - "Barlow = Back") :
Technique : The examiner flexes the infant's hips and knees to 90°. The examiner's thumb is placed along the inner medial thigh, and the index and middle fingers rest over the greater trochanter on the lateral hip. The examiner gently adducts the hip toward the midline while applying a gentle posterior force directed along the long axis of the femur.
Positive Finding : A palpable, tactile "clunk" as the unstable, subluxatable femoral head slips posteriorly over the fibrocartilaginous acetabular rim and dislocates out of the acetabulum.
Ortolani Maneuver (The Reduction Test - "Ortolani = Out / Open / back In") :
Technique : Following the Barlow maneuver, the hip is examined for reducibility. The examiner holds the hip flexed at 90° and gently abducts the thigh outward while simultaneously applying gentle anterior pressure by lifting the greater trochanter upward with the fingers.
Positive Finding : A palpable, tactile "clunk" as the dislocated femoral head slides smoothly anteriorly back over the acetabular rim into the acetabular cup.
Clinical Distinctions & Red Flags :
A palpable "clunk" (tactile sensation of displacement or reduction) indicates true hip instability or dislocation.
In contrast, high-pitched, soft, audible "clicks" are benign ligamentous snaps produced by the fascia lata or iliopsoas tendon sliding across bone and do not represent DDH.
Physical Signs in Older Infants (>2 to 3 Months) :
As soft tissues tighten, the Barlow and Ortolani maneuvers lose sensitivity. Signs of chronic dislocation become prominent:
Galeazzi (Allis) Sign : With the infant supine, feet flat on the table, and knees and hips flexed to 90°, the knee on the dislocated side sits noticeably lower than the normal side due to posterior and superior displacement of the femoral head.
Limited Abduction : Asymmetrical or restricted hip abduction (<60° of abduction) when the hips are flexed.
Asymmetric Skin Folds : Asymmetry of the gluteal, inguinal, or thigh skin creases (note: asymmetric thigh folds alone in neonates have low specificity, but asymmetrical gluteal or inguinal folds extending past the anal verge are clinically concerning).
Screening and Diagnostic Imaging Algorithm
Breech Presentation Mandate : According to AAP clinical guidelines, all female infants born in the breech position in the third trimester (≥34 weeks) must undergo bilateral hip ultrasonography at 4 to 6 weeks of age , regardless of physical examination findings. For male infants born breech, screening ultrasound is also strongly recommended.
Why Defer Imaging to 4–6 Weeks? : Transient neonatal hip laxity from maternal hormones resolves spontaneously in >80% of newborns within the first 3 to 4 weeks. Performing ultrasound prior to 4 weeks yields unacceptably high false-positive rates, leading to overtreatment.
Modality Selection: Ultrasound vs. Radiography :
Hip Ultrasonography : The definitive diagnostic imaging modality of choice from birth up to 4 to 6 months of age . Prior to 4 months, the neonatal femoral head is composed entirely of unossified radiolucent cartilage and cannot be visualized on plain X-rays. Dynamic ultrasound assesses the alpha angle (normal acetabular roof angle >60°) and femoral head coverage (>50%).
Plain Anteroposterior (AP) Pelvic Radiographs : Indicated after 4 to 6 months of age , once the secondary ossification center of the femoral capital epiphysis has visibly calcified. Evaluates disruption of Shenton's line (continuous smooth arc between the inferior border of the femoral neck and the superior pubic ramus) and the acetabular index.
Management of DDH
Infants <6 Months of Age : First-line management of a dislocated or subluxated reducible hip is the Pavlik Harness , a dynamic flexion-abduction orthosis that maintains the hips in 90° to 100° of flexion and 45° to 60° of abduction . Hyperabduction (>60°) must be strictly avoided because excessive compression can occlude the medial circumflex femoral vessels, causing avascular necrosis (AVN) of the femoral head , or compress the femoral nerve. The harness is worn continuously for 6 to 12 weeks with serial ultrasound monitoring.
Infants ≥6 Months of Age or Failed Harness : Closed reduction under general anesthesia with application of a rigid hip spica cast for 3 to 4 months. If closed reduction fails or for children diagnosed after 18 to 24 months, open surgical reduction with pelvic or femoral osteotomy is required.
Neonatal Hyperbilirubinemia
Jaundice (icterus) occurs in >60% of term and >80% of preterm infants during the first week of life, resulting from tissue deposition of bilirubin. Neonatal red blood cells have a shortened lifespan (70–90 days compared to 120 days in adults), neonates have twice the adult rate of bilirubin production, and their immature liver possesses deficient levels of the conjugating enzyme uridine diphosphoglucuronate-glucuronosyltransferase (UGT1A1) . Furthermore, the sterile neonatal intestine contains elevated concentrations of beta-glucuronidase , which hydrolyzes conjugated bilirubin back into unconjugated bilirubin, driving substantial enterohepatic recirculation.
Physiologic vs. Pathologic Jaundice
Physiologic Jaundice :
Manifests clinically after 24 hours of life (typically visible on day 2 or 3).
Total serum bilirubin (TSB) peaks between days 3 and 5 in full-term infants at 6 to 8 mg/dL (up to 10–12 mg/dL in formula-fed infants).
Bilirubin is predominantly unconjugated (indirect) .
Spontaneously resolves by 10 to 14 days of life in formula-fed infants (may persist up to 3 weeks in breastfed infants).
Infant is clinically well, vigorous, feeding well, and gaining weight appropriately.
Pathologic Jaundice Criteria (Any of the following constitutes pathologic jaundice) :
Clinical jaundice appearing within the first 24 hours of life (always pathologic until proven otherwise, usually indicative of hemolysis).
Rapid rate of total bilirubin rise >0.2 mg/dL per hour (or >5.0 mg/dL in 24 hours ).
Total serum bilirubin level exceeding the 95th percentile on the hour-specific Bhutani nomogram.
Conjugated (direct) bilirubin >1.0 mg/dL (or >20% of the total bilirubin level when total bilirubin is >5.0 mg/dL).
Clinical jaundice persisting beyond 14 days in a term infant or beyond 21 days in a preterm infant .
Infant exhibiting signs of acute illness: lethargy, vomiting, fever, dark tea-colored urine, or pale acholic (clay-colored) stools.
Etiologies of Pathologic Hyperbilirubinemia
Isoimmune Hemolytic Disease : ABO incompatibility (mother is blood group O; infant is group A or B; direct Coombs/DAT test positive or weakly positive; mild to moderate hemolysis) or Rh(D) isoimmunization (Rh-negative sensitized mother, Rh-positive infant; severe, rapid hemolysis; hydrops fetalis).
Erythrocyte Membrane & Enzyme Defects : Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency (X-linked; precipitated by oxidative triggers, infection, or spontaneous neonatal onset; common in Mediterranean, African, and Asian ancestry); hereditary spherocytosis (autosomal dominant, positive family history, elevated MCHC, negative Coombs test).
Extravasated Blood : Large cephalohematomas, extensive ecchymosis, or subgaleal hemorrhages; delayed breakdown of sequestered erythrocytes provides a prolonged bilirubin load.
Conjugated (Cholestatic) Hyperbilirubinemia : Never physiologic. Hallmarks are elevated direct bilirubin >1.0 mg/dL, dark amber urine, and acholic (white/clay) stools . The most time-critical diagnosis is biliary atresia (idiopathic progressive fibro-obliteration of the extrahepatic biliary tree). Early diagnosis via abdominal ultrasound and hepatobiliary scintigraphy (HIDA scan) followed by the Kasai procedure (hepatoportoenterostomy) before 45 to 60 days of life is vital to restore bile flow and prevent irreversible biliary cirrhosis and liver transplantation.
Breastfeeding Failure Jaundice vs. Breast Milk Jaundice
A classic board-exam challenge is differentiating jaundice related to inadequate lactation from jaundice induced by breast milk composition:
- Parameter Breastfeeding Failure Jaundice (Lactation Jaundice) Breast Milk Jaundice
- Timing of Onset Days 2 to 4 of life (early onset) Days 4 to 7 of life (late onset); peaks at weeks 2 to 3
Primary Mechanism Inadequate caloric and fluid intake; dehydration; delayed meconium transit; increased enterohepatic circulation of bilirubin Bioactive factors in mature maternal milk (high levels of beta-glucuronidase , free fatty acids, cytokines) that deconjugate bilirubin in bowel
Infant Clinical State Dehydrated, irritable, oliguria (<4–6 wet diapers/day), delayed stooling (meconium persists), weight loss >7% to 10% Thriving, vigorous infant , active suck, excellent weight gain (>20–30 g/day), copious pale yellow seedy stools, well-hydrated
Total Bilirubin Peak Peaks at day 3 to 5 (TSB often 12–18 mg/dL) Peaks at day 10 to 15 (TSB 12–20 mg/dL); may persist up to 8 to 12 weeks
Clinical Management Optimize lactation support, assess latch, increase feeding frequency to 8 to 12 times per 24 hours ; supplement with expressed breast milk or infant formula if weight loss >10% or severe dehydration; do NOT give plain water or dextrose water Reassurance ; continue exclusive breastfeeding; monitor bilirubin; phototherapy indicated only if TSB exceeds AAP threshold; breastfeeding cessation is NOT recommended
Acute Bilirubin Encephalopathy (ABE) & Kernicterus
Unconjugated bilirubin is highly lipid-soluble. When unbound bilirubin exceeds albumin-binding capacity (or crosses a permeable blood-brain barrier during sepsis, acidosis, or prematurity), it deposits in neuronal membranes, specifically targeting the globus pallidus, subthalamic nucleus, and cranial nerve auditory nuclei :
Acute Bilirubin Encephalopathy (ABE) :
Phase 1 (Early) : Lethargy, hypotonia, poor sucking, mild stupor. Reversible with urgent intervention.
Phase 2 (Intermediate) : Moderate stupor, irritability, alternating hypertonia and hypotonia, retrocollis (severe backward arching of the neck), opisthotonos (severe backward arching of the trunk), and a high-pitched, shrill cry . Fever may occur.
Phase 3 (Advanced) : Deep stupor or coma, persistent retrocollis and opisthotonos, pronounced shrill cry, seizures, apnea, and death.
Kernicterus (Chronic Bilirubin Encephalopathy) : Permanent, irreversible neurodevelopmental damage. The classic clinical tetrad includes:
Choreoathetoid Cerebral Palsy : Involuntary chorea, athetosis, and dystonic posturing.
Sensorineural Hearing Loss : Auditory neuropathy spectrum disorder due to brainstem auditory nuclei injury.
Upward Gaze Palsy : Limitation of upward vertical gaze (Parinaud-like syndrome).
Dental Enamel Dysplasia : Hypoplasia and green staining of primary teeth. Cognitive function may remain remarkably spared despite profound motor disability.
Management Guidelines (AAP 2022 Guidelines)
Intensive Phototherapy : Employs narrow-spectrum blue light (wavelength 460 to 490 nm ) with irradiance ≥30 µW/cm²/nm. Light penetrates the subcutaneous capillary beds, converting unconjugated 4Z,15Z-bilirubin via photoisomerization into lumirubin (a structural isomer) and configurational isomers. Lumirubin is water-soluble and excreted directly into bile and urine without requiring hepatic conjugation . The infant is stripped naked (except for a diaper) to maximize skin surface exposure, and opaque eye patches must be applied to prevent retinal phototoxicity.
Exchange Transfusion : Double-volume exchange transfusion (160 to 170 mL/kg) is indicated when total serum bilirubin reaches or exceeds the exchange threshold on AAP age- and risk-specific curves, or if the infant exhibits intermediate or advanced signs of acute bilirubin encephalopathy (retrocollis, opisthotonos, shrill cry), regardless of TSB level. Rapidly removes circulating unbound bilirubin and maternal antibodies while correcting severe hemolytic anemia.
Routine Newborn Preventive Prophylaxis
Immediate postpartum prophylaxis is a cornerstone of neonatal medicine, preventing devastating hemorrhagic, infectious, and metabolic complications before hospital discharge.
Intramuscular Vitamin K1 (Phytomenadione)
Dosing & Administration : Administer a single intramuscular dose of vitamin K1 (phytomenadione) 0.5 mg (infants ≤1,500 g) or 1.0 mg (infants >1,500 g) into the anterolateral thigh within 6 hours of birth .
Pathophysiology : Neonates are born with negligible hepatic stores of vitamin K because of poor placental transfer. Furthermore, human breast milk is notoriously deficient in vitamin K (containing only 1 to 3 µg/L compared to 50–100 µg/L in formula), and the neonatal gut is sterile at birth, lacking the bacterial microflora necessary for menaquinone synthesis. Vitamin K is an obligatory cofactor for post-translational gamma-glutamyl carboxylation of clotting factors II, VII, IX, and X , as well as regulatory proteins C and S .
Vitamin K Deficiency Bleeding (VKDB) Patterns :
Early VKDB (0 to 24 hours) : Typically occurs in neonates whose mothers took enzyme-inducing drugs that interfere with fetal vitamin K metabolism (e.g., antiepileptics: phenytoin, phenobarbital, carbamazepine; antituberculars: rifampin, isoniazid; vitamin K antagonists: warfarin). Presents with intra-abdominal bleeding, severe cephalohematoma, or intracranial hemorrhage.
Classic VKDB (Days 2 to 7) : Occurs in breastfed infants with delayed feeding who missed prophylaxis. Manifests as cutaneous bruising, oozing from the umbilical cord stump, puncture site hematomas, gastrointestinal hemorrhage (melena), or bleeding post-circumcision.
Late VKDB (Weeks 2 to 12) : The most lethal form, occurring almost exclusively in exclusively breastfed infants whose parents declined intramuscular vitamin K prophylaxis at birth . Presents catastrophically with intracranial hemorrhage in >50% of cases , manifesting as bulging fontanelle, vomiting, seizures, severe anemia, and coma, carrying a 20% to 30% mortality rate and permanent neurodevelopmental disability in survivors.
Coagulation Profile in VKDB : Markedly prolonged Prothrombin Time (PT/INR) and prolonged Activated Partial Thromboplastin Time (aPTT), with completely normal platelet count and normal fibrinogen levels .
Exam Pearl (Oral vs. IM Vitamin K) : Parental requests for oral vitamin K must be strongly counseled against. Oral regimens require complex multi-dose schedules (at birth, 1–2 weeks, and 4–8 weeks), have erratic intestinal absorption, rely on strict compliance, and have repeatedly failed to prevent late VKDB and intracranial hemorrhage in clinical trials. Intramuscular administration is the only proven, reliable prophylactic standard.
Erythromycin 0.5% Ophthalmic Ointment
Administration : A 1-cm ribbon of 0.5% erythromycin ophthalmic ointment is applied into the inferior conjunctival sac of each eye within 24 hours of birth (usually within 1 hour).
Indication : Mandatory prevention of gonococcal ophthalmia neonatorum ( Neisseria gonorrhoeae ) , which causes a hyperacute, hyperpurulent keratoconjunctivitis presenting within 2 to 5 days of birth that can rapidly progress to corneal ulceration, globe perforation, and permanent blindness.
CRITICAL BOARD EXAM PEARL : Topical erythromycin ointment DOES NOT prevent neonatal Chlamydia trachomatis conjunctivitis . Chlamydia is transmitted during passage through an infected birth canal and presents later, at 5 to 14 days of life , with watery eye discharge progressing to thick mucopurulent exudate, chemosis, and pseudomembrane formation. Topical antibiotic ointments are completely ineffective because Chlamydia colonizes the nasopharynx. The definitive treatment for chlamydial conjunctivitis is systemic oral erythromycin (50 mg/kg/day divided into 4 doses for 14 days) or oral azithromycin (20 mg/kg/day for 3 days), which eradicates nasopharyngeal colonization and prevents chlamydial interstitial pneumonia. Systemic macrolide therapy in infants younger than 6 weeks carries a small risk of infantile hypertrophic pyloric stenosis (IHPS) , requiring parental counseling regarding projectile non-bilious emesis.
Hepatitis B Immunization
Universal Birth Dose : All medically stable infants with birth weight ≥2,000 g should receive their first dose of monovalent Hepatitis B vaccine intramuscularly within 24 hours of birth .
Maternal HBsAg-Positive Protocol : If the mother is Hepatitis B surface antigen-positive (HBsAg-positive), the infant must receive BOTH the Hepatitis B vaccine AND Hepatitis B Immune Globulin (HBIG 0.5 mL) administered at separate anatomical injection sites (opposite anterolateral thighs) within 12 hours of birth . This dual immunoprophylaxis reduces vertical transmission risk from >90% to <5%. Post-vaccination serologic testing for anti-HBs and HBsAg is performed at 9 to 12 months.
Maternal HBsAg Status Unknown : Administer Hepatitis B vaccine within 12 hours of birth. Concurrently draw maternal blood for HBsAg. If the infant weighs ≥2,000 g, HBIG can be deferred until the maternal test returns positive (must be given within 7 days of birth). However, if the infant weighs <2,000 g , administer HBIG within 12 hours in addition to the vaccine, because low-birth-weight infants have suboptimal immune responses.
Preterm Infants (<2,000 g) Born to HBsAg-Negative Mothers : Delay the initial Hepatitis B vaccine dose until 1 month of chronological age or at hospital discharge, as immunogenicity before 2,000 g is reduced.
State Newborn Dried Blood Spot Screening
Every state mandates newborn metabolic and genetic screening collected via heel-stick capillary blood onto specialized filter paper (Guthrie card) between 24 and 48 hours of life , after the infant has established protein and lactose feedings. If blood is collected prior to 24 hours of life (e.g., early hospital discharge), a repeat dried blood spot must be drawn at 1 to 2 weeks of age.
Key Core Disorders on the Recommended Uniform Screening Panel (RUSP)
Phenylketonuria (PKU) : Autosomal recessive deficiency of phenylalanine hydroxylase (PAH) , which converts phenylalanine to tyrosine. Phenylalanine and neurotoxic phenylketones (phenylacetate, phenyllactate) accumulate. Untreated, children develop profound irreversible intellectual disability, microcephaly, seizures, behavioral disturbances, fair skin/blonde hair (impaired melanin synthesis), and a characteristic mousy or musty body odor . Treatment is lifelong dietary restriction of phenylalanine initiated within the first 7 to 10 days of life, maintaining blood phenylalanine between 120 and 360 µmol/L.
Congenital Hypothyroidism : Most common preventable cause of intellectual disability (incidence 1:2,000). Caused by thyroid dysgenesis (aplasia, hypoplasia, ectopia; 85%) or inborn errors of thyroxine synthesis (15%). Screened by elevated TSH and low total or free T4. Clinical symptoms at birth are subtle due to transplacental maternal T4: wide posterior fontanelle (>1 cm), prolonged unconjugated jaundice, poor feeding, lethargy, macroglossia, dry skin, coarse facies, umbilical hernia, and severe hypotonia. Treatment with oral levothyroxine (10 to 15 µg/kg/day) must be started within the first 2 weeks of life to preserve normal neurocognitive potential.
Galactosemia : Autosomal recessive deficiency of galactose-1-phosphate uridyltransferase (GALT) . Ingestion of galactose/lactose (in breast milk or cow's milk formula) leads to accumulation of toxic galactose-1-phosphate. Within days of feeding, the infant develops acute liver failure, hepatomegaly, jaundice, vomiting, hypoglycemia, renal tubular dysfunction (Fanconi syndrome), bilateral "oil-drop" cataracts, and a dramatic predisposition to fulminant Escherichia coli sepsis . Diagnosis: Elevated galactose-1-phosphate and absent GALT enzyme activity. Immediate management is strict, lifelong elimination of dietary galactose and lactose, transitioning immediately to a soy-based, elemental formula .
Hemoglobinopathies : Screened via high-performance liquid chromatography (HPLC) or isoelectric focusing. Identifies Sickle Cell Disease (HbSS, HbS/beta-thalassemia, HbSC). Early detection allows initiation of prophylactic oral penicillin V (125 mg PO twice daily) starting by 2 months of age , continuing until at least age 5 years, along with conjugate pneumococcal immunizations, which reduces the incidence of fatal invasive Streptococcus pneumoniae sepsis by >80%.
Cystic Fibrosis (CF) : Initial screening measures immunoreactive trypsinogen (IRT) , an enzyme precursor elevated in neonates with CF due to pancreatic ductular obstruction. Positive IRT triggers secondary CFTR mutation analysis (IRT/DNA strategy) or repeat IRT, followed by confirmation with a quantitative sweat chloride test (positive if ≥60 mmol/L). Early detection enables early pancreatic enzyme replacement therapy, fat-soluble vitamin (A, D, E, K) supplementation, and pulmonary clearance.
Severe Combined Immunodeficiency (SCID) : Screened by quantifying T-cell receptor excision circles (TRECs) , circular DNA fragments generated during normal T-cell receptor gene rearrangement in the thymus. A low or absent TREC count identifies profound T-cell lymphopenia. Infants with SCID appear healthy at birth but suffer fatal opportunistic infections (e.g., Pneumocystis jirovecii , disseminated viral infections) within months. Identification prompts immediate protective isolation, antimicrobial prophylaxis, absolute avoidance of live vaccines (rotavirus, BCG) , and curative hematopoietic stem cell transplantation (HSCT) before onset of life-threatening infection.
Critical Congenital Heart Disease (CCHD) Pulse Oximetry Screening
Non-invasive pulse oximetry screening detects asymptomatic ductal-dependent cyanotic congenital heart defects before ductal closure precipitates cardiogenic shock or sudden collapse. Tested lesions include hypoplastic left heart syndrome, pulmonary atresia, tetralogy of Fallot, total anomalous pulmonary venous return, transposition of the great arteries, tricuspid atresia, and truncus arteriosus.
Timing and Technique : Performed at ≥24 hours of life (or immediately prior to discharge if <24h). Pulse oximeter sensors are placed on the right hand (pre-ductal) and either foot (post-ductal) .
Algorithm Criteria :
Pass : SpO2 ≥95% in both the right hand and foot AND an absolute difference of ≤3% between them. Routine nursery care.
Immediate Fail (Positive Screen) : SpO2 <90% in either the right hand or foot. Requires immediate comprehensive clinical evaluation and urgent diagnostic echocardiography ; do not repeat screen.
Intermediate (Borderline) Screen : SpO2 90% to 94% in either extremity OR a difference >3% between right hand and foot. Repeat the measurement in 1 hour . If the second screen remains intermediate, repeat again in 1 hour . If three consecutive screens are intermediate, the screen is classified as a fail (positive screen) , mandating urgent echocardiogram prior to discharge.